XML 50 R43.htm IDEA: XBRL DOCUMENT v3.25.3
Stock-Based Plans and Compensation (Tables)
9 Months Ended
Sep. 30, 2025
Schedule of Stock-based Compensation Expense

There were no stock-based compensation expenses related to the 2013 Plan in the three and nine months ended September 30, 2025 and 2024. Total stock-based compensation expense related to the 2017 Plan was as follows:

 

Three Months Ended September 30,

 

 

2025

 

 

2024

 

 

Options

 

 

RSUs

 

 

Total

 

 

Options

 

 

RSUs

 

 

SARs

 

 

Total

 

Cost of revenue

$

197

 

 

$

868

 

 

$

1,065

 

 

$

285

 

 

$

1,057

 

 

$

 

 

$

1,342

 

Selling, general and administrative expense

 

233

 

 

 

7,922

 

 

 

8,155

 

 

 

499

 

 

 

7,607

 

 

 

2,315

 

 

 

10,421

 

Total

$

430

 

 

$

8,790

 

 

$

9,220

 

 

$

784

 

 

$

8,664

 

 

$

2,315

 

 

$

11,763

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30,

 

 

2025

 

 

2024

 

 

Options

 

 

RSUs

 

 

Total

 

 

Options

 

 

RSUs

 

 

SARs

 

 

Total

 

Cost of revenue

$

596

 

 

$

3,910

 

 

$

4,506

 

 

$

914

 

 

$

2,539

 

 

$

 

 

$

3,453

 

Selling, general and administrative expense

 

736

 

 

 

28,535

 

 

 

29,271

 

 

 

2,074

 

 

 

22,443

 

 

 

6,896

 

 

 

31,413

 

Total

$

1,332

 

 

$

32,445

 

 

$

33,777

 

 

$

2,988

 

 

$

24,982

 

 

$

6,896

 

 

$

34,866

 

 

Schedule of Common Stock Reserved for Future Issuance The Company has reserved certain stock of its authorized but unissued common stock for possible future issuance in connection with the following:

 

 

September 30,

 

 

2025

 

 

2024

 

Montrose 2013 Stock Incentive Plan

 

661,794

 

 

 

686,738

 

Montrose 2017 Stock Incentive Plan(1)

 

7,384,230

 

 

 

9,653,054

 

 

 

8,046,024

 

 

 

10,339,792

 

 

 

(1) In January 2025 and 2024, the Board of Directors ratified the addition of 1,372,373 and 1,207,563 shares of common stock, respectively, to the number of shares available for issuance under the 2017 Plan pursuant to the annual increase provision of such plan. Unless the Board of Directors determines otherwise, additional annual increases will be effective on each January 1, through January 1, 2027. The 2017 Plan permits the company to settle awards, if and when vested, in cash at its discretion. Pursuant to the terms of the 2017 Plan, the number of shares authorized for issuance thereunder will only be reduced with respect to shares of common stock actually issued upon exercise or settlement of an award. Shares of common stock subject to awards that have been canceled, expired, forfeited or otherwise not issued under an award and shares of common stock subject to awards settled in cash do not count as shares of common stock issued under the 2017 Plan. The Company expects to have sufficient shares available under the 2017 Plan to satisfy the future settlement of outstanding awards. Shares reserved for future issuance as of September 30, 2024 include 3,000,000 shares underlying the 3,000,000 2021 Performance SARs, which were cancelled effective as of December 31, 2024.

Montrose Amended & Restated 2017 Stock Incentive Plan  
Schedule of Restricted Stock Activity

RSAs and RSUs activity was as follows:

 

Nine Months Ended September 30,

 

 

2025

 

 

2024

 

 

Shares

 

 

Weighted-Average Grant Date Fair Value

 

 

Shares

 

 

Weighted-Average Grant Date Fair Value

 

Beginning outstanding shares

 

2,617,059

 

 

 

 

 

 

2,468,722

 

 

 

 

Granted

 

1,350,599

 

 

$

18.02

 

 

 

354,060

 

 

$

40.12

 

Forfeited/ cancelled

 

(104,996

)

 

$

28.44

 

 

 

(43,115

)

 

$

36.70

 

Vested

 

(617,957

)

 

$

27.21

 

 

 

(150,641

)

 

$

37.46

 

Ending outstanding shares

 

3,244,705

 

 

 

 

 

 

2,629,026

 

 

 

 

Summary of Stock Option Activity

The following summarizes the options activity of the 2017 Plan:

 

 

Options to Purchase Common Stock

 

 

Weighted-Average Exercise Price per Share

 

 

Weighted Average Grant Date Fair Value per Share

 

 

Weighted Average Remaining Contract Life (in Years)

 

 

Aggregate Intrinsic Value of In-The-Money Options

 

Outstanding as of December 31, 2023

 

2,516,272

 

 

$

30.92

 

 

$

15.95

 

 

 

7.0

 

 

$

13,825

 

Forfeited/ cancelled

 

(71,915

)

 

 

38.64

 

 

 

 

 

 

 

 

 

 

Expired

 

(20,510

)

 

 

45.57

 

 

 

 

 

 

 

 

 

 

Exercised

 

(51,524

)

 

 

26.21

 

 

 

 

 

 

 

 

 

732

 

Outstanding as of September 30, 2024

 

2,372,323

 

 

$

30.66

 

 

$

16.30

 

 

 

6.3

 

 

$

7,517

 

Outstanding as of December 31, 2024

 

2,345,207

 

 

$

30.62

 

 

 

16.32

 

 

 

6.0

 

 

 

776

 

Forfeited/ cancelled

 

(40,368

)

 

 

41.50

 

 

 

 

 

 

 

 

 

 

Expired

 

(65,287

)

 

 

36.89

 

 

 

 

 

 

 

 

 

 

Exercised

 

(16,804

)

 

 

15.45

 

 

 

 

 

 

 

 

 

164

 

Outstanding as of September 30, 2025

 

2,222,748

 

 

$

30.35

 

 

$

16.32

 

 

 

5.2

 

 

$

8,241

 

Exercisable as of September 30, 2025

 

1,995,520

 

 

$

29.11

 

 

 

 

 

 

5.1

 

 

$

8,241

 

Montrose Amended and Restated 2013 Stock Option Plan  
Summary of Stock Option Activity

The following summarizes the activity of the 2013 Plan:

 

 

Options to Purchase Common Stock

 

 

Weighted-Average Exercise Price per Share

 

 

Weighted Average Grant Date Fair Value per Share

 

 

Weighted Average Remaining Contract Life (in Years)

 

 

Aggregate Intrinsic Value of In-The-Money Options

 

Outstanding as of December 31, 2023

 

792,191

 

 

$

6.40

 

 

$

2.16

 

 

 

2.4

 

 

$

20,380

 

Exercised

 

(105,453

)

 

 

5.86

 

 

 

 

 

 

 

 

 

 

Outstanding as of September 30, 2024

 

686,738

 

 

$

6.49

 

 

$

2.49

 

 

 

1.8

 

 

$

13,606

 

Outstanding as of December 31, 2024

 

680,889

 

 

$

6.49

 

 

 

2.51

 

 

 

1.5

 

 

 

8,211

 

Expired

 

(1,000

)

 

 

6.03

 

 

 

 

 

 

 

 

 

 

Exercised

 

(18,095

)

 

 

8.02

 

 

 

 

 

 

 

 

 

309

 

Outstanding as of September 30, 2025

 

661,794

 

 

$

6.46

 

 

$

2.51

 

 

 

0.8

 

 

$

10,351

 

Exercisable as of September 30, 2025

 

661,794

 

 

$

6.45

 

 

 

 

 

 

0.8

 

 

$

10,351